Literature DB >> 10797135

Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides.

T Ahmed1, J Ungo, M Zhou, C Campo.   

Abstract

Inhaled heparin has been shown to inhibit allergic bronchoconstriction in sheep that develop only acute responses to antigen (acute responders) but was ineffective in sheep that develop both acute and late airway responses (LAR) (dual responders). Because the antiallergic activity of heparin is molecular-weight dependent, we hypothesized that heparin-derived oligosaccharides (<2, 500) with potential anti-inflammatory activity may attenuate the LAR in the dual-responder sheep. Specific lung resistance was measured in 24 dual-responder sheep before and serially for 8 h after challenge with Ascaris suum antigen for demonstration of early airway response (EAR) and LAR, without and after treatment with inhaled medium-, low-, and ultralow-molecular-weight (ULMW) heparins and "non-anticoagulant" fractions (NAF) of heparin. Airway responsiveness was estimated before and 24 h postantigen as the cumulative provocating dose of carbachol that increased specific lung resistance by 400%. Only ULMW heparins caused a dose-dependent inhibition of antigen-induced EAR and LAR and postantigen airway hyperresponsiveness (AHR), whereas low- and medium-molecular-weight heparins were ineffective. The effects of ULMW heparin and ULMW NAF-heparin were comparable and inhibited the LAR and AHR even when administered "after" the antigen challenge. The ULMW NAF-heparin failed to inhibit the bronchoconstrictor response to histamine, carbachol, and leukotriene D(4), excluding a direct effect on airway smooth muscle. In six sheep, segmental antigen challenge caused a marked increase in bronchoalveolar lavage histamine, which was not prevented by inhaled ULMW NAF-heparin. The results of this study in the dual-responder sheep demonstrate that 1) the antiallergic activity of inhaled "fractionated" heparins is molecular-weight dependent, 2) only ULMW heparins inhibit the antigen-induced EAR and LAR and postantigen AHR, and 3) the antiallergic activity is mediated by nonanticoagulant fractions and resides in the ULMW chains of <2,500.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797135     DOI: 10.1152/jappl.2000.88.5.1721

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

1.  The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells.

Authors:  A Smailbegovic; R Lever; C P Page
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Heparin normalizes allergen-induced nitric oxide deficiency and airway hyperresponsiveness.

Authors:  Harm Maarsingh; Jacob de Boer; Henk F Kauffman; Johan Zaagsma; Herman Meurs
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

3.  Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro.

Authors:  Rachel A Brown; Rebecca Lever; Neil A Jones; Clive P Page
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

Review 4.  Heparin oligosaccharides as potential therapeutic agents in senile dementia.

Authors:  Qing Ma; Umberto Cornelli; Israel Hanin; Walter P Jeske; Robert J Linhardt; Jeanine M Walenga; Jawed Fareed; John M Lee
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

5.  Synthetic di-sulfated iduronic acid attenuates asthmatic response by blocking T-cell recruitment to inflammatory sites.

Authors:  Motohiro Nonaka; Xingfeng Bao; Fumiko Matsumura; Sebastian Götze; Jeyakumar Kandasamy; Andrew Kononov; David H Broide; Jun Nakayama; Peter H Seeberger; Minoru Fukuda
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-16       Impact factor: 11.205

6.  Inhibition of allergic airway responses by heparin derived oligosaccharides: identification of a tetrasaccharide sequence.

Authors:  Tahir Ahmed; Gregory Smith; Iontcho Vlahov; William M Abraham
Journal:  Respir Res       Date:  2012-01-23

Review 7.  Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes.

Authors:  Fahad Akhtar; Xinyu Wan; Gang Wu; Samuel Kesse; Shaoda Wang; Shuying He
Journal:  Molecules       Date:  2018-07-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.